| XERIS BIOPHARMA HOLDINGS |
| USA |
| Gesundheit |
| US98422E1038 / A3C4ZC |
| 2B30 (Frankfurt) / XERS (NASDAQ) |
| FRA:2B30, ETR:2B30, 2B30:GR, NASDAQ:XERS |
| - |
| https://www.xerispharma.c.. |
|
Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for chronic endocrine and neurological diseases. Xeris Biopharma Holdings, Inc. markets Gvoke, a ready-to-use liquid gl..
>Volltext.. |
| 1580.44 Mio. EUR |
| 1727.65 Mio. EUR |
| 295.78 Mio. EUR |
| 43.56 Mio. EUR |
| -15.14 Mio. EUR |
| -0.08 EUR |
| 255.24 Mio. EUR |
| 107.36 Mio. EUR |
| 49.92 Mio. EUR |
| 0.64 |
| 40.62% |
| 44.67% |
| - |
| - |
| - |
| XERIS |
| 30.09.26 |